Literature DB >> 24376947

Dosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer.

Cemile Ceylan1, Nadir Kucuk1, Hande Bas Ayata1, Metin Guden1, Kayihan Engin1.   

Abstract

AIM: The aim of our study was the dosimetric and physical evaluation of the CK and IMRT treatment plans for 16 patients with localized prostate cancer.
BACKGROUND: Intensity modulated radiation therapy (IMRT) is one of the recent technical advances in radiotherapy. The prostate is a well suited site to be treated with IMRT. The challenge of accurately delivering the IMRT needs to be supported by new advances such as image-guidance and four-dimensional computed conformal radiation therapy (4DCRT) tomography. CyberKnife (CK) provides real time orthogonal X-ray imaging of the patient during treatment course to follow gold fiducials installed into the prostate and to achieve motion correlation between online acquired X-ray imaging and digital reconstructed radiographs (DRRs) which are obtained from planning computed tomography images by translating and rotating the treatment table in five directions. METHODS AND MATERIALS: Sixteen IMRT and CK plans were performed to be compared in terms of conformity (CI), heterogeneity indices (HI), percentage doses of 100% (V100), 66% (V66), 50% (V50), 33% (V33) and 10% (V10) volumes of the bladder and rectum. Dose-volume histograms for target and critical organs, (CI) and indices (HI) and isodose lines were analyzed to evaluate the treatment plans.
RESULTS: Statistically significant differences in the percentage rectal doses delivered to V10, V33, and V50 of the rectum were detected in favor of the CK plans (p values; <0.001, <0.001 and 0.019, respectively). The percentage doses for V66 and V100 of the rectum were larger in CK plans (13%, 2% in IMRT and 21%, 3% in CK plans, respectively). Percentage bladder doses for V10 and V33 were significantly lower in CK plans [96% in IMRT vs 48% in CK (p < 0.001) and 34% in IMRT vs 24% in CK (p = 0.047)]. Lower percentage doses were observed for V50, V66 of the bladder for the IMRT. They were 5.4% and 3.45% for IMRT and 13.4% and 8.05% for CK, respectively. Median CI of planning target volume (PTV) for IMRT and CK plans were 0.94 and 1.23, respectively (p < 0.001).
CONCLUSION: Both systems have a very good ability to create highly conformal volumetric dose distributions. Median HI of PTV for IMRT and CK plans were 1.08 and 1.33, respectively (p < 0.001).

Entities:  

Keywords:  CyberKnife; IMRT; Prostate; Radiosurgery

Year:  2010        PMID: 24376947      PMCID: PMC3863154          DOI: 10.1016/j.rpor.2010.10.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  28 in total

1.  Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison.

Authors:  G O De Meerleer; L A Vakaet; W R De Gersem; C De Wagter; B De Naeyer; W De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  Fractionation and protraction for radiotherapy of prostate carcinoma.

Authors:  D J Brenner; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

3.  Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression.

Authors:  Linda van de Bunt; Uulke A van der Heide; Martijn Ketelaars; Gerard A P de Kort; Ina M Jürgenliemk-Schulz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-22       Impact factor: 7.038

4.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

5.  Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Authors:  Jonathan B Ashman; Michael J Zelefsky; Margie S Hunt; Steven A Leibel; Zvi Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

6.  Role of IMRT in reducing penile doses in dose escalation for prostate cancer.

Authors:  Anil Sethi; Najeeb Mohideen; Leonid Leybovich; John Mulhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

7.  Patient setup and verification for intensity-modulated radiation therapy (IMRT).

Authors:  Andrew O Jones; Marc T Kleiman
Journal:  Med Dosim       Date:  2003       Impact factor: 1.482

8.  What hypofractionated protocols should be tested for prostate cancer?

Authors:  Jack F Fowler; Mark A Ritter; Rick J Chappell; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

9.  Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement.

Authors:  Elizabeth J Adams; David J Convery; Vivian P Cosgrove; Helen A McNair; John N Staffurth; Jaap Vaarkamp; Christopher M Nutting; Alan P Warrington; Steve Webb; Jan Balyckyi; David P Dearnaley
Journal:  Radiother Oncol       Date:  2004-01       Impact factor: 6.280

Review 10.  Cyberknife: A double edged sword?

Authors:  Bindhu Joseph; Sanjay S Supe; Aruna Ramachandra
Journal:  Rep Pract Oncol Radiother       Date:  2010-07-06
View more
  12 in total

1.  Development of raster scanning IMRT using a robotic radiosurgery system.

Authors:  Hiroya Shiomi; Yuichi Akino; Iori Sumida; Norihisa Masai; Ryoong-Jin Oh; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2021-03-10       Impact factor: 2.724

2.  Utilization of cone-beam CT for offline evaluation of target volume coverage during prostate image-guided radiotherapy based on bony anatomy alignment.

Authors:  Petr Paluska; Josef Hanus; Jana Sefrova; Lucie Rouskova; Jakub Grepl; Jan Jansa; Linda Kasaova; Miroslav Hodek; Milan Zouhar; Milan Vosmik; Jiri Petera
Journal:  Rep Pract Oncol Radiother       Date:  2012-05-05

3.  The importance of accurate treatment planning, delivery, and dose verification.

Authors:  Julian Malicki
Journal:  Rep Pract Oncol Radiother       Date:  2012-03-06

4.  Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml.

Authors:  Jiri Kubeš; Cvek Jakub; Vondráček Vladimir; Dvořák Jan; Argalacsová Sona; Navrátil Matej; Buřil Jan
Journal:  Rep Pract Oncol Radiother       Date:  2012-02-09

5.  Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer.

Authors:  Trinitat García Hernández; Aurora Vicedo González; Jorge Pastor Peidro; Juan V Roselló Ferrando; Luis Brualla González; Domingo Granero Cabañero; José López Torrecilla
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-08

Review 6.  The future of Radiation Oncology: Considerations of Young Medical Doctor.

Authors:  Bartosz Urbański
Journal:  Rep Pract Oncol Radiother       Date:  2012-10-04

7.  Comparison of dose volume histograms for supine and prone position in patients irradiated for prostate cancer-A preliminary study.

Authors:  Tomasz Bajon; Tomasz Piotrowski; Andrzej Antczak; Bartosz Bąk; Barbara Błasiak; Joanna Kaźmierska
Journal:  Rep Pract Oncol Radiother       Date:  2011-02-01

8.  Evaluation of combining bony anatomy and soft tissue position correction strategies for IMRT prostate cancer patients.

Authors:  Marta Adamczyk; Tomasz Piotrowski; Ewa Adamiak
Journal:  Rep Pract Oncol Radiother       Date:  2012-02-09

9.  Does CyberKnife improve dose distribution versus IMRT and VMAT on a linear accelerator in low-risk prostate cancer?

Authors:  Dorota Maria Borowicz; Agnieszka Skrobała; Marta Kruszyna-Mochalska; Julian Malicki
Journal:  Radiol Oncol       Date:  2022-03-28       Impact factor: 4.214

10.  Dosimetric and radiobiological comparison of CyberKnife M6™ InCise multileaf collimator over IRIS™ variable collimator in prostate stereotactic body radiation therapy.

Authors:  Vindu Kathriarachchi; Charles Shang; Grant Evans; Theodora Leventouri; Georgios Kalantzis
Journal:  J Med Phys       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.